The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model
Abstract
OBJECTIVE: The pleiotropic cytokine interleukin (IL)-6 seems to play a pivotal role in sepsis, but contradictory findings in animal models impede a rationale for therapies directed against IL-6. IL-6 signals by two mechanisms via the ubiquitous transmembrane glycoprotein 130 (gp130): "classic" signaling using membrane-bound IL-6 receptor (IL-6R) and trans-signaling using soluble IL-6R (sIL-6R). Trans-signaling is selectively inhibited by soluble gp130 (sgp130). The aim of this study was to systematically compare complete blockade of IL-6 signaling (using a neutralizing anti-IL-6 antibody) and selective blockade of IL-6 trans-signaling (using a fusion protein of sgp130 and the crystallizable fragment of immunoglobulin G1, sgp130Fc) in a standardized cecal ligation and puncture (CLP) sepsis model. DESIGN: Animal study. SETTING: Animal laboratory. SUBJECTS: C57BL/6J mice. INTERVENTIONS: We performed a 96-hr dose-response study and a 24-hr study to investigate short-term mechanisms. In the 96-hr study, CLP was performed in 120 randomized mice (20 mice received vehicle, 10 mice per dose group). Mice were treated with equimolar doses of sgp130Fc (0.01/0.1/1/10 mg/kg) or anti-IL-6 (0.008/0.08/0.8/8 mg/kg) 24 hrs before CLP. Two additional groups received 0.5 mg/kg sgp130Fc 24 hrs before or 1 mg/kg sgp130Fc 24 hrs after CLP. Survival and activity scores were obtained daily until 96 hrs after CLP. In the 24-hr study, mice were randomized into four groups with 10 animals each (sham/vehicle, CLP/vehicle, CLP/anti-IL-6 [0.8 mg/kg], and CLP/sgp130Fc [1 mg/kg]) and killed after 24 hrs. MEASUREMENTS AND MAIN RESULTS: In contrast to anti-IL-6, pretreatment with sgp130Fc significantly and dose-dependently increased survival from 45% to 100%. In addition, 1 mg/kg sgp130Fc administered 24 hrs after CLP increased survival from 45% to 80%. Mechanistically, sgp130Fc efficacy was reflected by complete prevention of epithelial cell apoptosis in the jejunum after CLP, which was not achieved with anti-IL-6. CONCLUSION: Selective inhibition of IL-6 trans-signaling by sgp130Fc has considerable potential for the treatment of sepsis and related disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibition of trans signaling via gp130 blockade in murine sepsis models rescues mice from widespread inflammation and death (41).”
From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [41]
Citations
Cites
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationApoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction
Hotchkiss, R. S., Swanson, P. E., Freeman, B. D., Tinsley, K. W., Cobb, J. P., Matuschak, G. M., Buchman, T. G., & Karl, I. E. (1999) · Critical Care Medicine · doi:10.1097/00003246-199907000-00002 · Cited by 1,341
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V. W. M., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,124
Multiple-Organ-Failure Syndrome
Carrico, C. J. (1986) · Archives of Surgery · doi:10.1001/archsurg.1986.01400020082010 · Cited by 819
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationHubbard, W. J., Choudhry, M. A., Schwacha, M. G., Kerby, J. D., Rue, L. W., Bland, K. I., & Chaudry, I. H. (2005) · Shock · doi:10.1097/01.shk.0000191414.94461.7e · Cited by 801
[Multiple organ failure syndrome].
Simbirtsev, S. A., Beliakov, N. A., & Konychev, A. V. (1988) · PubMed · Cited by 796
Soluble receptors for cytokines and growth factors: generation and biological function
Rose‐John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 777
Self-citationBone, R. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-8-199610150-00009 · Cited by 718 · cited 1×
“T he cytokine interleukin-6 (IL-6) appears to be an important player in sepsis (1, 2), and a correlation between high IL-6 plasma levels and mortality in septic patients has been observed (3, 4).”
BackgroundSoluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M., & Rose-John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 665
Self-citation
Research works printed but not linked: 5
- Peters, 1998, Blood, 92, 3495, 10.1182/blood.V92.10.3495 · DOI
- Narazaki, 1993, Blood, 82, 1120, 10.1182/blood.V82.4.1120.1120 · DOI · Paper page
- Chaudry, 1979, Surgery, 85, 205
- Nieuwenhuijzen, 1996, Eur J Surg, 162, 259
- Pastores, 1996, Am J Gastroenterol, 91, 1697
Cited by
Sorted by citations
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Self-citationMacrophage Cytokines: Involvement in Immunity and Infectious Diseases
Arango Duque, G., & Descoteaux, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00491 · Cited by 2,708
“Inhibition of trans signaling via gp130 blockade in murine sepsis models rescues mice from widespread inflammation and death (41).”
BackgroundIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S. R., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,132
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
Self-citationInterleukin-6 Family CytokinesPreprint
Rose‐John, S. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 846
Self-citationEndothelial Responses in Sepsis
Joffre, J., Hellman, J., İnce, C., & Ait‐Oufella, H. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-1911tr · Cited by 751
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 719
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose‐John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 689
Self-citationCOVID-19 infection: an overview on cytokine storm and related interventions
Montazersaheb, S., Khatibi, S. M. H., Hejazi, M. S., Tarhriz, V., Farjami, A., Sorbeni, F. G., Farahzadi, R., & Ghasemnejad, T. (2022) · Virology Journal · doi:10.1186/s12985-022-01814-1 · Cited by 657
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationInterleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose‐John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 532
Self-citationThe IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Garbers, C., Aparicio-Siegmund, S., & Rose‐John, S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.008 · Cited by 432
Self-citationInterplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 399
Macrophage polarization and meta-inflammation
Li, C., Xu, M. M., Wang, K., Adler, A. J., Vella, A. T., & Zhou, B. (2017) · Translational research · doi:10.1016/j.trsl.2017.10.004 · Cited by 376
Historical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 329
Self-citationInterleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Self-citationIL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
Zhang, H., Neuhöfer, P., Song, L., Rabe, B., Lesina, M., Kurkowski, M. U., Treiber, M., Wartmann, T., Regnér, S., Thorlacius, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64931 · Cited by 294
Self-citationTranssignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice
Schuett, H., Oestreich, R., Waetzig, G. H., Annema, W., Luchtefeld, M., Hillmer, A., Bavendiek, U., von Felden, J., Divchev, D., Kempf, T., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.229435 · Cited by 243
Self-citationThe role and therapeutic targeting of IL-6 in rheumatoid arthritis
Narazaki, M., Tanaka, T., & Kishimoto, T. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1295850 · Cited by 224
Magro, G. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100029 · Cited by 214
The Two-Faced Cytokine IL-6 in Host Defense and Diseases
Narazaki, M., & Kishimoto, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113528 · Cited by 214
Garbers, C., Thaiss, W. M., Jones, G. W., Waetzig, G. H., Lorenzen, I., Guilhot, F., Lissilaa, R., Ferlin, W. G., Grötzinger, J., Jones, S. A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295758 · Cited by 196
Self-citationCytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality
Que, Y., Hu, C., Wan, K., Hu, P., Wang, R., Luo, J., Li, T., Ping, R., Hu, Q., Sun, Y., et al. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1884248 · Cited by 167
The soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Self-citationInterleukin-6 signalling in health and disease
Rose‐John, S. (2020) · F1000Research · doi:10.12688/f1000research.26058.1 · Cited by 167
Self-citationAntiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19
Thimmulappa, R. K., Mudnakudu-Nagaraju, K. K., Shivamallu, C., Subramaniam, K., Radhakrishnan, A., Bhojraj, S., & Kuppusamy, G. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06350 · Cited by 168
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology
Giraldez, M. D., Carneros, D., Garbers, C., Rose-John, S., & Bustos, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00473-x · Cited by 156
Self-citationIL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling
Hoge, J., Yan, I., Jänner, N., Schumacher, V., Chalaris, A., Steinmetz, O. M., Engel, D. R., Scheller, J., Rose‐John, S., & Mittrücker, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201044 · Cited by 158
Self-citationDistinct Effects of IL-6 Classic and Trans -Signaling in Bone Fracture Healing
Prystaz, K., Kaiser, K., Kovtun, A., Haffner-Luntzer, M., Fischer, V., Rapp, A. E., Liedert, A., Strauss, G., Waetzig, G. H., Rose-John, S., et al. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.10.011 · Cited by 142
Self-citationten Berge, J. C., Fazil, Z., van den Born, L. I., Wolfs, R. C. W., Schreurs, M. W. J., Dik, W. A., & Rothova, A. (2019) · Acta Ophthalmologica · doi:10.1111/aos.13899 · Cited by 118
IL‐6 Trans‐signaling Controls Liver Regeneration After Partial Hepatectomy
Fazel Modares, N., Polz, R., Haghighi, F., Lamertz, L., Behnke, K., Zhuang, Y., Kordes, C., Häussinger, D., Sorg, U. R., Pfeffer, K., et al. (2019) · Hepatology · doi:10.1002/hep.30774 · Cited by 113
Self-citationInterleukin-6 in Sepsis and Capillary Leakage Syndrome
Krüttgen, A., & Rose‐John, S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0062 · Cited by 107
Self-citationADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Schumacher, N., & Rose‐John, S. (2019) · Cancers · doi:10.3390/cancers11111736 · Cited by 108
Self-citationReparative and Maladaptive Inflammation in Tendon Healing
Arvind, V., & Huang, A. H. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.719047 · Cited by 107
Ullah, M. A., Revez, J. A., Loh, Z., Simpson, J., Zhang, V., Bain, L., Varelias, A., Rose‐John, S., Blumenthal, A., Smyth, M. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.02.032 · Cited by 100
Self-citationYeo, E. C. F., Brown, M. P., Gargett, T., & Ebert, L. M. (2021) · Cells · doi:10.3390/cells10030607 · Cited by 98
Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?
Reiss, A. B., Siegart, N. M., & Leon, J. D. (2017) · Clinical Lipidology · doi:10.1080/17584299.2017.1319787 · Cited by 94
The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases
Wang, M.-J., Zhang, H.-L., Chen, F., Guo, X.-J., Liu, Q.-G., & Hou, J. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00527-1 · Cited by 84
“Furthermore, sgp130Fc administration, but not anti-IL-6, is more likely to improve the survival in the mice models of cecal ligation and puncture, abdominal aortic aneurysms, and acute lung injury [95–97].”
BackgroundHitting a complex target: an update on interleukin-6 trans-signalling
Waetzig, G. H., & Rose‐John, S. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.660307 · Cited by 83
Self-citationPrairie, É., Côté, F., Tsakpinoglou, M., Mina, M., Quiniou, C., Leimert, K. B., Olson, D. M., & Chemtob, S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.12.004 · Cited by 74
Kaiser, K., Prystaz, K., Vikman, A., Haffner‐Luntzer, M., Bergdolt, S., Strauß, G., Waetzig, G. H., Rose‐John, S., & Ignatius, A. A. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1483-7 · Cited by 72
Self-citationSoluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome
Chen, L. Y. C., Biggs, C. M., Jamal, S., Stukas, S. K., Wellington, C. L., & Sekhon, M. S. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100269 · Cited by 71
The Neurobiology of Bipolar Disorder: An Integrated Approach
Muneer, A. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.18 · Cited by 68
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome
Du, P. F., Geng, J., Wang, F., Chen, X., Huang, Z., & Wang, Y. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.53564 · Cited by 71
Burton, M. D., & Johnson, R. W. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.10.008 · Cited by 68
Gebremariam, H. G., Qazi, K. R., Somiah, T., Pathak, S. K., Sjölinder, H., Sverremark‐Ekström, E., & Jonsson, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02326 · Cited by 66
Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease
Schumertl, T., Lokau, J., Rose‐John, S., & Garbers, C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119143 · Cited by 68
Self-citationSodenkamp, J., Waetzig, G. H., Scheller, J., Seegert, D., Grötzinger, J., Rose‐John, S., Ehlers, S., & Hölscher, C. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.01.015 · Cited by 66
Self-citationYan, I., Schwarz, J., Lücke, K., Schumacher, N., Schumacher, V., Schmidt, S., Rabe, B., Saftig, P., Donners, M., Rose-John, S., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0515-207r · Cited by 67
Self-citationIL-6 and its role in IgA nephropathy development
Groza, Y., Jemelková, J., Kafkova, L. R., Malý, P., & Raška, M. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.04.001 · Cited by 67
Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates
Paige, E., Clément, M., Lareyre, F., Sweeting, M. J., Raffort, J., Grenier, C., Finigan, A. J., Harrison, J. E., Peters, J. E., Sun, B. B., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002413 · Cited by 64
Self-citationDissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer
Garbers, C., & Rose‐John, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7568-6_11 · Cited by 63
Self-citationLokau, J., Agthe, M., & Garbers, C. (2016) · Mediators of Inflammation · doi:10.1155/2016/1785021 · Cited by 62
Maresin 1 Mitigates Inflammatory Response and Protects Mice from Sepsis
Li, R., Wang, Y., Ma, Z., Ma, M., Wang, D., Xie, G., Yin, Y., Zhang, P., & Tao, K. (2016) · Mediators of Inflammation · doi:10.1155/2016/3798465 · Cited by 60
Physiological role of cytokines in the regulation of mammalian metabolism
Baat, A. D., Trinh, B., Ellingsgaard, H., & Donath, M. Y. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.06.002 · Cited by 62
IL-6 Trans-Signaling Drives Murine Crescentic GN
Braun, G. S., Nagayama, Y., Maruta, Y., Heymann, F., van Roeyen, C. R. C., Klinkhammer, B. M., Boor, P., Villa, L., Salant, D. J., Raffetseder, U., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111147 · Cited by 58
Self-citationWei, L., Chou, C., Chen, M., Rose‐John, S., Kuo, M., Chen, S., & Yang, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3462 · Cited by 56
Self-citationMilne, S. B., Li, X., Yang, C. X., Cordero, A. I. H., Filho, F. S. L., Yang, C. W. T., Shaipanich, T., van Eeden, S. F., Leung, J. M., Lam, S. C., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00130-2021 · Cited by 55
Muresan, M. G., Balmoș, I. A., Badea, I., & Santini, A. (2018) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2018-0023 · Cited by 54
Therapeutic targeting of IL-6 trans-signaling
Rose‐John, S. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155577 · Cited by 52
Self-citationThe soluble interleukin-6 receptor and related proteins
Rose‐John, S. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.07.001 · Cited by 51
Self-citationBlocking only the bad side of IL-6 in inflammation and cancer
Rose‐John, S. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155690 · Cited by 44
Self-citationProteolytic control of Interleukin-11 and Interleukin-6 biology
Lokau, J., Agthe, M., Flynn, C. M., & Garbers, C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.008 · Cited by 43
Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
Boslem, E., Reibe, S., Carlessi, R., Smeuninx, B., Tegegne, S., Egan, C. L., McLennan, E., Terry, L. V., Nobis, M., Mu, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0831 · Cited by 39
Self-citationVella, R., Panci, D., Carini, F., Malta, G., Vieni, S., David, S., Albano, G. D., Puntarello, M., Zerbo, S., & Argo, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1682306 · Cited by 47
The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
Stolarczyk, M., & Scholte, B. J. (2018) · Mediators of Inflammation · doi:10.1155/2018/1067134 · Cited by 39
Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130
Morieri, M. L., Passaro, A., & Zuliani, G. (2017) · Mediators of Inflammation · doi:10.1155/2017/1396398 · Cited by 40
The Regenerative Activity of Interleukin-6
Galun, E., & Rose-John, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-308-4_4 · Cited by 34
Self-citationJiang, S., Shi, D., Bai, L., Niu, T., Kang, R., & Liu, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110169 · Cited by 36
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Mahmud-Al-Rafat, A., Majumder, A., Rahman, K. M. T., Hasan, A. M. M., Islam, K. M. D., Taylor-Robinson, A. W., & Billah, M. M. (2019) · Cytokine · doi:10.1016/j.cyto.2018.12.008 · Cited by 34
Colás-Algora, N., Muñoz-Pinillos, P., Cacho-Navas, C., Ortiz, J. A., de Rivas, G., Barroso, S., López‐Collazo, E., & Millán, J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319695 · Cited by 33
Mentzelopoulos, S., & Zakynthinos, S. (2017) · Resuscitation · doi:10.1016/j.resuscitation.2017.10.013 · Cited by 27
Teoh, H., Quan, A., Creighton, A., Bang, K. W. A., Singh, K. K., Shukla, P. C., Gupta, N., Pan, Y., Lovren, F., Leong-Poi, H. M., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.214 · Cited by 32
Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Chalaris, A., Schmidt‐Arras, D., Yamamoto, K., & Rose‐John, S. (2012) · Digestive Diseases · doi:10.1159/000341698 · Cited by 33
Self-citationFeeding-induced resistance to acute lethal sepsis is dependent on hepatic BMAL1 and FXR signalling
Geiger, S. S., Traba, J., Richoz, N., Farley, T. K., Brooks, S. R., Petermann, F., Wang, L., Gonzalez, F. J., Sack, M. N., & Siegel, R. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22961-z · Cited by 31
Alves, J. D., & Paula, F. S. (2013) · Biologics · doi:10.2147/btt.s35475 · Cited by 31
Fadanni, G. P., & Calixto, J. Β. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.07.002 · Cited by 27
Guven‐Maiorov, E., Acuner, S. E., Keskin, Ö., Gürsoy, A., & Nussinov, R. (2014) · Cancers · doi:10.3390/cancers6020663 · Cited by 26
Srinivasan, A., Ekambaram, S. P., Selvan, P. S., Aruldhas, J., & Erusappan, T. (2019) · Journal of Food Biochemistry · doi:10.1111/jfbc.13116 · Cited by 25
Interleukin-6 drives endothelial glycocalyx damage in COVID-19 and bacterial sepsis
Drost, C. C., Rovas, A., Osiaevi, I., Schughart, K., Lukasz, A. H., Linke, W. A., Pavenstädt, H. J., & Kümpers, P. (2024) · Angiogenesis · doi:10.1007/s10456-024-09916-w · Cited by 27
IL-6 potentiates tumor resistance to photodynamic therapy (PDT)
Brackett, C. M., Owczarczak, B., Ramsey, K. D., Maier, P. G., & Gollnick, S. O. (2011) · Lasers in Surgery and Medicine · doi:10.1002/lsm.21107 · Cited by 24
Modern anti-cytokine therapy of autoimmune diseases
Astrakhantseva, I., Efimov, G., Drutskaya, M., Kruglov, A. A., & Nedospasov, S. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914120049 · Cited by 27
Nullens, S., Staessens, M., Peleman, C., Plaeke, P., Malhotra‐Kumar, S., Francque, S., Man, J. G. D., & Winter, B. Y. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152914 · Cited by 26
The Role of gp130 Cytokines in Tuberculosis
Ritter, K., Rousseau, J., & Hölscher, C. (2020) · Cells · doi:10.3390/cells9122695 · Cited by 24
Characteristic Cytokine Profiles of Aqueous Humor in Glaucoma Secondary to Sturge-Weber Syndrome
Peng, C., Wu, Y., Ding, X., Chen, D., Zeng, C., Xu, L., & Guo, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00004 · Cited by 22
In Search of a Cure for Sepsis: Taming the Monster in Critical Care Medicine
Okeke, E. B., & Uzonna, J. E. (2016) · Journal of Innate Immunity · doi:10.1159/000442469 · Cited by 21
Can we design a better anti-cytokine therapy?
Drutskaya, M. S., Efimov, G. A., Kruglov, A., & Nedospasov, S. A. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ma0117-025r · Cited by 20
Rodríguez-Hernández, M. Á., Baena-Bustos, M., Carneros, D., Zurita-Palomo, C., Muñoz-Pinillos, P., Millán, J., Padillo, F. J., Smerdou, C., von Kobbe, C., Rose‐John, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105132 · Cited by 19
Self-citationLee, S., Kim, N. Y., Chung, C., Park, D., Kang, D. H., Kim, D. K., Yeo, M., Sun, P., & Lee, J. E. (2025) · BMC Immunology · doi:10.1186/s12865-024-00679-z · Cited by 21
Gesiorowski, A., Ettich, J., Werner, J., Wittich, C., Pieper, S., Padrini, G., Behnke, K., Floss, D. M., Lang, P. A., Moll, J. M., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105343 · Cited by 18
Self-citationJan, J., Chou, Y.-C., Cheng, Y., Chen, C., Huang, W., & Hsiao, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071394 · Cited by 19
Circulating levels of sgp130 and sex hormones in male patients with coronary atherosclerotic disease
Cui, Y., Dai, W., & Li, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.002 · Cited by 19
Srinivasan, A., Aruldhas, J., Selvan, P. S., & Ekambaram, S. P. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13563 · Cited by 18
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival
Kleinegger, F., Hofer, E. M., Wodlej, C., Golob‐Schwarzl, N., Birkl-Toeglhofer, A. M., Stallinger, A., Petzold, J., Orlova, A., Krassnig, S., Reihs, R., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.006 · Cited by 18
Self-citationScreening of Sepsis Biomarkers Based on Bioinformatics Data Analysis
Liang, G.-B., Li, J., Pu, S., & He, Z. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/6788569 · Cited by 17
Zhang, Y., Hu, J., Zuo, W., He, P., Xue, Q., Feng, X., Zhang, Y., & Maze, M. (2022) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006250 · Cited by 17
Kang, S., Onishi, S., Ling, Z., Inoue, H., Zhang, Y., Chang, H., Zhao, H., Wang, T., Okuzaki, D., Matsuura, H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315898120 · Cited by 17
Modeling the Intra- and Extracellular Cytokine Signaling Pathway under Heat Stroke in the Liver
Rodriguez-Fernández, M., Grosman, B., Yuraszeck, T. M., Helwig, B. G., Leon, L. R., & Doyle, F. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073393 · Cited by 16
Metadata
- Authors
- Barkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., Seegert, D., Krettek, C., & Waetzig, G. H.
- Affiliations
- Christian-Albrechts-Universität zu Kiel (DE)
- ORCID
- Venue
- Critical Care Medicine
- Published
- 2011-06
- Volume
- 39
- Issue
- 6
- Pages
- 1407-1413
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2319958192
- Cited by
- 169
- References
- 50
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 11 · 2023: 13 · 2022: 10 · 2021: 20 · 2020: 10 · 2019: 15 · 2018: 9 · 2017: 15 · 2016: 9 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- interleukin-6, IL-6 trans-signaling, soluble gp130, sgp130Fc, soluble IL-6 receptor, anti-IL-6 antibody, polymicrobial sepsis, cecal ligation and puncture, sepsis mortality, cytokine inhibition, IL-6 receptor signaling, dose-response relationship
- MeSH terms
- Interleukin-6 Inhibitors, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Male, Mice, Inbred C57BL, Recombinant Fusion Proteins, Signal Transduction, Interleukin-6, Sepsis, Mice, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
